Cannabinoid and Psychedelic Pharmacology and Drug Development

Cannabinoid and Psychedelic Pharmacology and Drug Development

por Jim Mitchell and Google NotebookLM
QuímicaCiencias de la Vida
Temporada 4

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 15 Label Accuracy in Cannabinoid Products

This episode explores label accuracy in cannabinoid products, with a focus on the challenges and importance of proper labeling in the CBD/THC industry. The discussion covers research from JAMA showing widespread mislabeling issues, the potential dangers of inaccurate labels for consumers, and the critical role of third-party testing and cGMP compliance in ensuring product safety. The conversation also delves into lesser-known cannabinoids like CBG, CBN, and THCV, examining their unique properties and potential benefits.
T4 · E18
31 ene 2025
10:42

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 16 Label Accuracy in Psychedelic Products

This podcast episode explores the critical importance of label accuracy in psilocybin products, drawing parallels to early challenges in the cannabis industry. The discussion covers key topics including: - The use of advanced testing methods like LCMS (liquid chromatography mass spectrometry) to accurately measure psilocybin and psilocin levels - Current challenges in the unregulated market, described as a "Wild West" environment with varying product quality and potency - The FDA's emerging role in regulation through PDUFA guidelines - Special considerations for different product forms, including dried mushrooms, extracts, and microdosing products The episode emphasizes how accurate labeling is fundamental to consumer safety, market trust, and the responsible development of the psychedelic industry.
T4 · E19
31 ene 2025
29:34

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 17 Critical Material Attributes (CMAs) in Cannabis and Psychedelic Manufacturi

This podcast episode explores Critical Material Attributes (CMAs) in botanical drug manufacturing, focusing on cannabis and psychedelics. The discussion covers key aspects including: - The unique challenges of working with botanical materials compared to synthetic drugs - Important CMAs like moisture content, particle size, and microbial load that affect product quality - How cultivar selection impacts chemical profiles and final product characteristics The episode emphasizes how consistent CMAs are fundamental to ensuring product safety, quality, and regulatory compliance in botanical drug manufacturing
T4 · E20
31 ene 2025
17:28

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 18 Process Analytical Technology (PAT) in Natural Products

This podcast episode explores Process Analytical Technology (PAT) and its transformative impact on manufacturing natural products, particularly cannabinoids and psychedelics. The discussion covers key analytical tools like NIR and Raman spectroscopy, explaining how they enable real-time quality control and monitoring during production. The episode highlights PAT's benefits including reduced waste, improved efficiency, and better regulatory compliance. It also addresses important considerations about implementation costs, sustainability benefits, and the ethical implications for workforce development.
T4 · E21
31 ene 2025
18:31

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 19 Product Lifecycle Management and Post-Approval Changes

This episode explores pharmaceutical product lifecycle management, focusing on what happens after FDA drug approval. It explains how companies can make post-approval changes through different regulatory pathways (CBE0, CBE30, and PAS). The discussion covers Quality by Design (QbD) principles, mutagenic impurities, and the unique challenges of botanical drug development. The episode emphasizes the importance of regulatory frameworks in maintaining drug safety and efficacy while allowing for necessary manufacturing improvements and innovations.
T4 · E22
31 ene 2025
13:28

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 20 Safety Considerations Beyond the Lab (Societal and Ethical Implications)

This podcast episode explores the societal safety implications of cannabinoids and psychedelics, covering key topics like addiction potential, psychological risks, and substance misuse. The discussion examines how regulatory frameworks and quality control measures like cGMP compliance can help ensure public safety. The episode also delves into the FDA's role in drug approval, the importance of accurate labeling, and the broader ethical considerations of integrating these substances into mainstream use.
T4 · E23
31 ene 2025
21:56

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 21 Clinical Trial Design Nuances for Psychedelic Therapies

This podcast episode explores the complex challenges of designing clinical trials for psychedelic therapies, particularly focusing on unique issues like the placebo effect and functional unblinding. The discussion covers how researchers use active placebos and creative trial designs to control for expectation bias. It also examines the FDA's stance on regulating psychedelic therapy, highlighting the complex relationship between drug approval and therapeutic context. The episode emphasizes the importance of standardized therapy protocols while maintaining flexibility for individual experiences.
T4 · E24
31 ene 2025
14:47

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 22 Clinical Trial Design Nuances for Cannabinoid Therapies

This podcast episode explores the complexities and challenges of clinical trials for cannabinoid therapies. The discussion covers key aspects including: - Dosing variability and product consistency challenges in plant-derived compounds - Patient compliance and addressing stigma around cannabis research - Placebo control difficulties unique to cannabinoid studies - Special considerations for vulnerable populations like children and pregnant women The episode also examines promising therapeutic applications including chronic pain management, multiple sclerosis treatment, and potential cancer-related applications.
T4 · E25
31 ene 2025
21:44

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 23 Pharmacovigilance and Post-Marketing Surveillance

This podcast episode explores pharmacovigilance and post-market surveillance in cannabinoid and psychedelic therapies. The discussion covers how the FDA monitors drug safety after approval, the importance of real-world data collection, and the role of Risk Evaluation and Mitigation Strategies (REMS) in ensuring patient safety. The speakers examine unique challenges in monitoring these therapies, including drug interactions, subjective effects, and the importance of set and setting. They also discuss how technology and collaborative efforts between healthcare providers, researchers, and patients contribute to building a comprehensive safety framework for these emerging treatments.
T4 · E26
31 ene 2025
23:12

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 24 Intellectual Property, Patents, and Regulatory Exclusivities

This podcast episode explores intellectual property rights in cannabinoid and psychedelic drug development. The discussion covers various aspects of patent protection, including novel drug formulations, extraction processes, and synthetic analogs. The speakers examine the tension between protecting pharmaceutical innovations and ensuring treatment accessibility, while also addressing the ethical considerations of patenting naturally-derived compounds. The episode delves into topics like orphan drug status for rare diseases and emerging alternative models like open-source research platforms. Throughout the conversation, there's a focus on balancing commercial interests with equitable access to these potentially groundbreaking therapies.
T4 · E27
31 ene 2025
18:04
15 de 26